Peptide Library / Detail
IGF-1 DES
Half-life
20-30 minutes
Delivery
Subcutaneous injection
Dosage
—
Research Use Only
All products listed are for laboratory research only — not for human consumption. By browsing, you acknowledge these terms.
Purchase
Description
IGF-1 DES (des(1-3)IGF-1) is a truncated variant of insulin-like growth factor-1 that lacks the first three amino acids at the N-terminus. This modification results in significantly reduced binding to IGF binding proteins, allowing for more localized tissue effects and increased potency compared to standard IGF-1. It is primarily researched for its potential in muscle growth, tissue repair, and metabolic regulation.
Usage
Research protocols typically involve subcutaneous administration at dosages ranging from 50-150 mcg per day, often divided into multiple doses. Timing is commonly pre- or post-workout to maximize localized effects in target tissues. Research cycles generally range from 4-8 weeks with appropriate monitoring of glucose metabolism and IGF-1 levels.
Mechanism of Action
IGF-1 DES binds to IGF-1 receptors with high affinity but has drastically reduced binding to IGF binding proteins (IGFBPs) due to its truncated structure. This allows for enhanced local tissue activity and more direct anabolic signaling through the PI3K/Akt and MAPK pathways, promoting protein synthesis, cellular proliferation, and glucose uptake. The compound demonstrates particular efficacy in tissues where it is administered due to its limited systemic distribution.
Benefits(7)
- Enhanced localized muscle growth and hypertrophy
- Improved muscle tissue repair and recovery
- Increased protein synthesis in target tissues
- Reduced binding to IGFBPs allows for more potent tissue-specific effects
- Potential improvements in glucose metabolism and insulin sensitivity
- May support connective tissue repair and bone health
- Shorter half-life allows for more controlled dosing strategies
Side Effects(8)
- Hypoglycemia due to enhanced insulin-like effects on glucose metabolism
- Joint pain or stiffness from rapid tissue growth
- Potential for localized tissue overgrowth at injection sites
- Headaches and fatigue
- Jaw discomfort or facial changes with long-term use
- Increased risk of insulin resistance with chronic use
- Potential cardiovascular strain and organ growth with excessive dosing
- Possible increased cancer cell proliferation risk in susceptible individuals